ResMed, Verily to form JV to help reach millions of untreated sleep apnea sufferers
ResMed and Verily announced an agreement to form a new joint venture. The U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions to more efficiently identify, diagnose, treat and manage sleep apnea. July 11, 2018